Le Dr Avi Beri est spécialisé dans les interventions sur la prostate au Sourasky Medical Center, notamment la résection transurétrale de la prostate (RTUP).
Avec plus de 42 années d'expérience chirurgicale, le Dr Joseph Klauzner est spécialisé dans les procédures colorectales, pancréatiques et gastro-intestinales.
Le Dr Hughes Hyun est spécialisé dans la chirurgie mini-invasive et robotique, aidant les patients à récupérer plus rapidement.
Le Dr Zengin apporte plus de _doctor_8416_ années d'expérience en urologie et exerce actuellement à l'hôpital Lokman Hekim Akay.
Le Dr George Tie est spécialisé dans les chirurgies de la prostate mini-invasives, y compris la TUIP, au Ponderas Academic Hospital.
Le professeur associé Ozkan Onuk est spécialisé dans les procédures urologiques à l'hôpital Medical Park Bahcelievler et mène des recherches approfondies sur les traitements de la prostate.
Le Dr Mustafa Serkan Alemdar est spécialisé dans les procédures TUIP au complexe hospitalier Medical Park Antalya, apportant une vaste expertise dans les interventions urologiques.
Formé au Memorial Sloan-Kettering Cancer Centre de New York, le Dr Navarro Vilches est spécialisé dans les chirurgies urologiques avancées à Quirónsalud Marbella.
Le Prof. Dr. Kadir Önem est professeur d'urologie à l'hôpital Medical Park de Samsun. Il a obtenu son diplôme de médecine et a terminé sa spécialisation en urologie à l'Université d'Istanbul. Il a ensuite effectué un stage postdoctoral au Baylor College of Medicine en neuro-urologie, urologie reconstructrice et oncologie urologique. Il traite des cas neuro-urologiques et reconstructeurs complexes chez les adultes et les enfants. Il a développé des techniques chirurgicales.
Il est chercheur principal dans plusieurs essais internationaux de phase III–IV sur la vessie neurologique et le cancer de la vessie. Il est l'auteur de plus de 70 publications et chapitres de livres. Il exerce en tant qu'examinateur pour de nombreuses revues médicales.
Leadership et affiliations : Président, Association Urologique Turque – Branche de la mer Noire occidentale (2025). Comité de prévention de l'ISCoS (2025). Groupe de neuro-urologie de l'EAU (2023–2025). Comité de neuro-urologie de l'ICS (2023–2025). Conseil d'administration de l'INUS (2023). Prix : TUA (2016, 2017, 2020, 2022) et ICS (2020).
Spécialisé dans les procédures urologiques, y compris les chirurgies de la prostate ouvertes et fermées dans les hôpitaux Büyük Anadolu.
Le Dr Yaacov Lawrence est chef du service de radio-oncologie au centre médical Sheba. Il est spécialisé dans la radiothérapie de précision et la neuro-oncologie. Le Dr Lawrence a été un pionnier de la radiochirurgie du plexus cœliaque pour la gestion de la douleur liée au cancer du pancréas. Il détient le titre de FASTRO, l'une des plus hautes distinctions dans sa spécialité.
Le Dr Dorit Zilberman est urologue senior au Sheba Medical Center en Israël. Elle est pionnière en chirurgie urologique robotique et mini-invasive. Le Dr Zilberman traite les cancers du rein, de la vessie et de la prostate. Elle a contribué au lancement du programme de chirurgie robotique da Vinci à Sheba. Forbes Israël l'a reconnue parmi les meilleurs médecins du pays.
Le professeur associé Cem Basatac est spécialisé en urologie avec un accent sur la chirurgie laparoscopique à l'hôpital Gayrettepe Florence Nightingale.
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
Le médecin est un spécialiste en urologie hautement expérimenté, occupant le poste de chef du service d'urologie à l'hôpital Quirónsalud Torrevieja depuis 2017. Titulaire d'un diplôme de médecine et d'une spécialisation de l'Université Johannes Gutenberg en Allemagne, le médecin possède une vaste expérience clinique remontant à 2007. L'expertise du médecin couvre l'urologie oncologique, les maladies de la prostate et les affections complexes des voies urinaires.
Un axe majeur de la pratique du médecin est la chirurgie urologique robotisée, utilisant spécifiquement le système chirurgical Da Vinci pour les interventions liées au cancer de la prostate. Le médecin a contribué à la littérature académique, notamment par des chapitres dans « Differentialdiagnose Urologie », et s'attache à fournir des soins de haute qualité aux patients locaux et internationaux.
Le Dr Ozkan est spécialisé dans le traitement des maladies de la prostate par TUIP dans les hôpitaux Büyük Anadolu.
Spécialisé dans la RIRS et les chirurgies de la prostate ouvertes et fermées, y compris la TUIP, dans les hôpitaux Büyük Anadolu.
Le Dr Daniel Leszczynski apporte _doctor_9996_ années d'expertise en urologie, se spécialisant dans les procédures mini-invasives telles que la TUIP au Carolina Hospital.
A réalisé plus de 2 500 biopsies de fusion de la prostate – Le Dr Czarniecki est spécialisé dans les thérapies robotiques et le traitement focal au Carolina Hospital.
Le médecin est un spécialiste en urologie hautement expérimenté avec une vaste carrière s'étendant sur plus de trois décennies. Après avoir obtenu son diplôme de la faculté de médecine de l'Université d'Uludağ en 1988, le médecin a terminé un programme de spécialisation en urologie en 1997. Le médecin a atteint le rang de professeur associé en 2006 et a obtenu le titre de professeur en 2011.
Tout au long d'une carrière distinguée, le médecin a occupé de nombreux postes de direction, notamment en tant que chef du département d'urologie dans plusieurs hôpitaux universitaires et en tant que superviseur éducatif et administratif dans de grands hôpitaux de formation et de recherche. Le médecin possède une expertise approfondie en urologie clinique, ayant servi dans diverses institutions médicales publiques et privées à travers la Turquie.